Similar Papers

Paper Title
Journal
Date
Author
Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.
D V Quon ... R I Baker
Haemophilia : the official journal of the World Federation of Hemophilia | VOL. 23
D V Quon, et. al.D V Quon ... R I Baker
11 Dec 2016
Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
Roshni Kulkarni ... Baisong Mei
Blood | VOL. 126
Roshni Kulkarni, et. al.Roshni Kulkarni ... Baisong Mei
03 Dec 2015
Long-Term Efficacy of rFVIIIFc Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia A
Bryce A Kerlin ... Geoffrey Allen
Blood | VOL. 126
Bryce A Kerlin, et. al.Bryce A Kerlin ... Geoffrey Allen
03 Dec 2015
Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a
Michael Wang ... Nisha Jain
Blood | VOL. 128
Michael Wang, et. al.Michael Wang ... Nisha Jain
02 Dec 2016
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
A novel therapy with a rational design for AML.
Maria L Amaya
Blood | VOL. 145
Maria L AmayaMaria L Amaya
30 Jan 2025
For how long has this problem been there?
Niccolò Bolli ... Matteo Claudio Da Vià
Blood | VOL. 145
Niccolò Bolli, et. al.Niccolò Bolli ... Matteo Claudio Da Vià
30 Jan 2025
Targeting CD47: many misses; hopeful for a hit.
Lindsay Wilde ... Margaret Kasner
Blood | VOL. 145
Lindsay Wilde, et. al.Lindsay Wilde ... Margaret Kasner
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.